Muerte súbita en pacientes con enfermedad renal crónica avanzada

Caravaca, Francisco; Chávez, Edgar; Alvarado, Raúl; García-Pino, Guadalupe; Luna, Enrique

doi:10.1016/j.nefro.2016.05.001

Cited by 9 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The factors associated with progression of CKD may be classified as modifiable and not modifiable [1,2]. Among the non-modifiable factors, we have the initial kidney function, race, sex, age, birth weight and specific genetic factors.…”

Section: Discussionmentioning

confidence: 99%

“…In our study, the progression of CKD was significantly associated with the increase in age and male gender. Among the modifiable factors are proteinuria, high blood pressure, poor glycemic control in diabetes, dyslipidemia, uric acid, use of nephrotoxic-medication, among others [1,2]. Proteinuria is an independent risk factor most important in the progression of CKD [7,9,10].…”

Section: Discussionmentioning

confidence: 99%

“…Possible factors associated with progression have been identified as the etiology of kidney failure, proteinuria, metabolic control of diabetes, hypertension, smoking, dyslipidemia, calcium, phosphorus, uric acid, and use of nephrotoxics, among others [2] Some of these factors are associated with rapid progression such as diabetic nephropathy, chronic glomerulonephritis and polycystic kidney disease of the adult. Hypertensive vascular disease and tubulointerstitial nephropathies are associated with slow progression [1,2]. Proteinuria, in addition to being a marker of kidney damage, is a factor associated with rapid progression and is a cardiovascular risk factor [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…Proteinuria, in addition to being a marker of kidney damage, is a factor associated with rapid progression and is a cardiovascular risk factor [3,4]. The evidence for the effect of the correction of these factors to reduce the speed of progression or the correction of CKD is contradictory, although its benefit on cardiovascular risk has been demonstrated at other levels [1,2]. The objective of the present prospective study was to determine the factors associated with the progression of CKD in a population of adults over 65 years of age.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Progression of Chronic Kidney Disease in over 65-year-old Nephroprotection Program Patients in Colombia

Machado¹

2023

Rev. Colomb. Nefrol.

View full text Add to dashboard Cite

Background: Studies evaluating chronic kidney disease in older adults are scarce despite the high prevalence of the disease in this age group. In this study we have tried to determine the factors associated with the progression of chronic kidney disease in a group of patients over 65 years old. Methods: An analytical observational study of a prospective non-concurrent cohort was performed. We included patients older than 65 years belonging to a nephroprotection program and then, we followed them for 12 months. The variables of interest were age, sex, history of diabetes mellitus, serum creatinine at baseline and at 12-month follow-up, blood pressure and use of antihypertensive drugs, high density lipoprotein and low density lipoprotein, cholesterol levels, proteinuria, and use of antiplatelet agents. The estimated glomerular filtration rate (eGFR) was calculated at baseline and at 12-month follow-up, lastly the progression of chronic kidney disease was established. Results: 200 patients were included with an average age of 78.9 + 7.6 years, 51% (102) females, 33% (66) with a history of diabetes mellitus, with a mean initial eGFR 38.8 + 12.1 mL/min/1.73 m2. The mean of the final eGFR was 36.4 + 11.0 mL/min/ 1.73 m2; 17.5% (35) presented a decrease > 25% of the initial eGFR (progression) and 37.5% (75) showed a decrease > 5mL/min/1.73m2/ year (rapid progression). Progression and rapid progression were significantly associated with age (p = 0.03 and p = 0.001, respectively), male sex (p <0.001 and p <0.001, respectively) and proteinuria (p <0.001 and p <0.001, respectively). There were no significant associations with other variables of interest. Conclusion: In our study, the progression of chronic kidney disease in patients older than 65 years in a nephroprotection program was significantly associated with the increased age, male sex, and presence of proteinuria.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Progression of Chronic Kidney Disease in over 65-year-old Nephroprotection Program Patients in Colombia

Machado¹

2023

Rev. Colomb. Nefrol.

View full text Add to dashboard Cite

show abstract

“…In healthy individuals, serum phosphate concentrations are maintained primarily by the major organs, including the intestines, kidneys, and bones [1][2][3]. Chronic kidney disease (CKD) often presents with elevated serum phosphorus levels and end-stage renal failure because the ability to excrete phosphate through the kidney is compromised, leading to hyperphosphatemia.…”

Section: Introductionmentioning

confidence: 99%

Effects of the novel sodium-dependent phosphate cotransporter 2b inhibitor DZ1462 on hyperphosphatemia in chronic kidney disease

2024

Am J Transl Res

View full text Add to dashboard Cite

Background: Serum phosphate levels remain insufficiently controlled in chronic kidney disease (CKD) patients, and novel therapeutic strategies are needed. Blocking intestinal phosphate absorption mediated by sodiumdependent phosphate cotransporter type 2b (NPT2b) holds promise as one such strategy. Methods: The in vitro cellular potency of DZ1462 was evaluated using a radioactive Pi uptake assay on stable Chinese hamster ovary (CHO) cell clones transfected with human NPT2b (hNPT2b) or rat NPT2b (rNPT2b). The ability of DZ1462 to inhibit phosphate absorption was studied in vivo in an acute model after oral bolus challenge with 33 PO 4 and in an adenineinduced chronic hyperphosphatemia rat model. PK and minitox was also evaluated. Results: The cellular assays with the hNPT2b-CHO and rNPT2b-CHO clones showed that DZ1462 significantly and potently inhibited phosphate uptake. In vivo, in a chronic Pi-fed rat model, DZ1462 effectively inhibited intestinal Pi uptake. In a hyperphosphatemia rat model, DZ1462 significantly inhibited Pi uptake, and DZ1462 in combination with sevelamer had a synergistic effect. The pharmacokinetics (PK) study confirmed that DZ1462 is a gastrointestinal (GI)-restricted compound that can remain in the intestine for a sufficient duration. In addition, DZ1462 also reduced cardiovascular events and ameliorated osteoporosis in a CKD animal model. Conclusions: This study revealed that a GI-restricted NPT2b inhibitor DZ1462 potently inhibits NPT2b in vitro and blocks intestinal phosphate uptake in multiple animal models with potential to reduce various cardiovascular events in CKD models. Therefore, DZ1462 may be useful to treat renal disease patients who have shown an unsatisfactory response to phosphate binders.

show abstract

Left Ventricular Mechanical Dispersion and Global Longitudinal Strain and Ventricular Arrhythmias in Predialysis and Dialysis Patients

Hensen

Goossens

Podlesnikar

et al. 2018

Journal of the American Society of Echocardiography

View full text Add to dashboard Cite

show abstract

Muerte súbita en pacientes con enfermedad renal crónica avanzada

Abstract: SCD is relatively common in non-dialysis advanced CKD patients. SCD was closely related to age and comorbidity, and some indirect data from this study suggest that unrecognised or undertreated cardiovascular disease may predispose to a higher risk of SCD.

Cited by 9 publications

References 26 publications

Progression of Chronic Kidney Disease in over 65-year-old Nephroprotection Program Patients in Colombia

Progression of Chronic Kidney Disease in over 65-year-old Nephroprotection Program Patients in Colombia

Effects of the novel sodium-dependent phosphate cotransporter 2b inhibitor DZ1462 on hyperphosphatemia in chronic kidney disease

Left Ventricular Mechanical Dispersion and Global Longitudinal Strain and Ventricular Arrhythmias in Predialysis and Dialysis Patients

Contact Info

Product

Resources

About